Therapeutic effects of methotrexate encapsulated in hyaluronic acid-coated exosomes derived from Wharton's jelly mesenchymal stem cells in a rat model of rheumatoid arthritis | Synapse
March 3, 2026
Therapeutic effects of methotrexate encapsulated in hyaluronic acid-coated exosomes derived from Wharton's jelly mesenchymal stem cells in a rat model of rheumatoid arthritis
Key Points
Methotrexate encapsulated in exosomes significantly reduces inflammation in the rat model of rheumatoid arthritis.
Treatment led to a 40% decrease in joint swelling within two weeks, indicating strong therapeutic potential.
Employing exosomes from Wharton's jelly mesenchymal stem cells allowed targeted delivery of the drug.
This approach may enable future advances in rheumatoid arthritis treatment strategies.